XML 46 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Pay vs Performance Disclosure [Table]        
Pay vs Performance [Table Text Block]
Pay versus Performance
As required by Item 402(v) of Regulation S-K, we are providing the following disclosure regarding executive compensation paid to our CEO and principal executive officer ("PEO"), Kevin Sayer, and our NEOs other than our CEO (the "Other NEOs"), and company performance for the fiscal years listed below. Our Compensation Committee did not consider the pay versus performance disclosure below in making its pay decisions for any of the years shown. For further information concerning our pay-for-performance philosophy and how we structure our executive compensation to drive and reward performance, refer to “Executive Compensation—Compensation Discussion and Analysis”. The amounts shown below are calculated in accordance with Item 402(v) of Regulation S-K.
Value of Initial Fixed $100 Investment Based On:
Year
Summary Compensation Table Total for PEO
$ (1)
Compensation Actually Paid to PEO
$ (1)(4)(5)
Average Summary Compensation Table Total for Other NEOs
$ (2)
Average Compensation Actually Paid to Other NEO s
$ (2)(4)(5)
Total Shareholder Return
$ (6)
Peer Group Total Shareholder Return
$ (6)
Net Income
(in millions)
$ (7)
Company Selected Measure: Revenue (8)
(in millions)
$
202315,712,24422,999,0975,015,5776,071,441226.9299.63541.5 3,608.6 
202215,435,6525,735,7024,440,9753,929,405207.08105.61341.2 2,964.9 
(9)
202111,985,32436,052,0764,962,0606,403,115245.47137.80216.9 2,422.5 
(10)
202013,804,15645,122,4635,707,75010,335,589
(3)
169.02133.15549.7 1,926.7 
(11)
(1)Kevin Sayer was our PEO for fiscal years 2023, 2022, 2021, and 2020.
(2)Other NEOs include:
2023: Jereme Sylvain, Michael Brown, Teri Lawver, and Jake Leach;
2022: Jereme Sylvain, Michael Brown, Girish Naganathan, and Jake Leach;
2021: Jereme Sylvain, Paul Flynn, Jake Leach, Chad Patterson, and Quentin Blackford.
2020: Quentin Blackford, Rick Doubleday, Jake Leach, and Jeff Moy.
(3)Mr. Moy and Mr. Doubleday received acceleration of time-based vesting for outstanding equity awards pursuant to Mr. Moy's retention incentive agreement dated April 2020 and Mr. Doubleday's transition and consulting agreement dated December 2020. The modifications of the RSUs are reflected above as of the modification date of April 28, 2020 for Mr. Moy and December 10, 2020 for Mr. Doubleday.
      
Named Executive Officers, Footnote [Text Block] Kevin Sayer was our PEO for fiscal years 2023, 2022, 2021, and 2020.
(2)Other NEOs include:
2023: Jereme Sylvain, Michael Brown, Teri Lawver, and Jake Leach;
2022: Jereme Sylvain, Michael Brown, Girish Naganathan, and Jake Leach;
2021: Jereme Sylvain, Paul Flynn, Jake Leach, Chad Patterson, and Quentin Blackford.
2020: Quentin Blackford, Rick Doubleday, Jake Leach, and Jeff Moy.
      
PEO Total Compensation Amount $ 15,712,244 $ 15,435,652 $ 11,985,324 $ 13,804,156
PEO Actually Paid Compensation Amount $ 22,999,097 5,735,702 36,052,076 45,122,463
Adjustment To PEO Compensation, Footnote [Text Block] The 2023 Summary Compensation Table ("SCT") totals reported for the PEO and the average of the Other NEOs for each year were subject to the following adjustments per Item 402(v)(2)(iii) of Regulation S-K to calculate “compensation actually paid" or CAP:
2023
PEO
($)
Average for Other NEOs
($)
Summary Compensation Table15,712,2445,015,577 
Adjustments for Grant Date Fair Value
Deductions for equity awards reported in Summary Compensation Table(12,486,939)(3,753,911)
Adjustments for Changes in Equity Fair Value
Year-end Fair Value of Equity Awards Granted During the Year that Remained Unvested as of the End of the Covered Year18,259,324 4,485,281 
Vesting Date Fair Value for Awards Granted and Vested in the Same Fiscal Year— — 
Change in Year-end Fair Value of Equity Awards Granted During Prior Years that Remained Unvested as of the End of the Covered Year1,297,572 285,998 
Change in Fair Value from Prior Year-end to Vesting Date for Awards Granted in Prior Years that Vested in Covered Fiscal Year216,896 38,496 
Prior Year-End Fair Value for Awards Granted in Prior Years that are forfeited during the Covered Year— — 
Net Increases for the Inclusion of Rule 402(v) Equity Values19,773,792 4,809,775 
Compensation Actually Paid22,999,097 6,071,441 
(5)The SCT totals reported for the PEO and the average for the Other NEOs for each year were subject to the adjustments as required by Regulation S-K Item 402(v) (2)(iii) to calculate “compensation actually paid. Equity values are calculated in accordance with ASC Topic 718, and the valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of the grant.
(6)$100 invested on December 31, 2019 in Dexcom common stock or the S&P Health Care Equipment index, including reinvestment of any dividends. Our 2022 Proxy Statement included the total shareholder return of the Nasdaq Medical Equipment index. As a result of the discontinuation of the Nasdaq Medical Equipment index in 2022, we believe that the S&P Health Care Equipment Select Industry index is a more appropriate index for comparison of our stock performance. Accordingly, the table above reflects the cumulative total stockholder return of the S&P Health Care Equipment Select Industry index. Using the Nasdaq Medical Equity index, and assuming $100 invested on December 31, 2019, including reinvestment of any dividends, the Peer Group Shareholder Return for 2022, 2021 and 2020 was $97.35, $144.19 and $139.52, respectively.
(7)We adopted ASU 2020-06 as of January 1, 2020 on a full retrospective basis and have reflected the adoption in the table above.
(8)We have identified 2023 Adjusted Revenue as described in the Compensation Discussion and Analysis, as the most important financial performance measure used to link compensation actually paid to the PEO and Other NEOs for 2023 to the Company’s performance. We may determine a different financial performance measure to be the most important financial performance measure in future years. A reconciliation of this Non-GAAP financial measure to its nearest GAAP comparable financial measure is included in Annex A.
(9)For a description of 2022 revenue, please refer to our 2023 Proxy Statement.
(10)For a description of 2021 revenue, please refer to our 2022 Proxy Statement.
(11)For a description of 2020 revenue, please refer to our 2021 Proxy Statement. 		     
Non-PEO NEO Average Total Compensation Amount $ 5,015,577 4,440,975 4,962,060 5,707,750
Non-PEO NEO Average Compensation Actually Paid Amount $ 6,071,441 3,929,405 6,403,115 10,335,589
Compensation Actually Paid vs. Total Shareholder Return [Text Block]
Total compensation for the PEO and Other NEOs, as disclosed in the Summary Compensation Table, is comprised of salaries, annual cash incentives, and equity awards. The CAP calculation for each year includes changes in fair market value adjustments on vesting and outstanding equity awards during the year. The CAP adjustment fluctuates due to changes in the Company's stock price in each of the years presented.
The following graph shows the relationship between the CAP to our PEO, average CAP to our Other NEOs, and Dexcom's cumulative total shareholder return, or TSR, and the peer group's cumulative TSR (S&P Health Care Equipment index) for the fiscal years ended December 31, 2023, 2022, 2021 and 2020.
      
Compensation Actually Paid vs. Net Income [Text Block]
The following graph shows the relationship between the CAP to our PEO, the average CAP to our Other NEOs, and the Company's net income for the fiscal years ended December 31, 2023, 2022, 2021 and 2020.
4271
      
Compensation Actually Paid vs. Company Selected Measure [Text Block]
The following graph shows the relationship between the CAP to our PEO, the average CAP to our Other NEOs, and the Company's Revenue for the fiscal years ended December 31, 2023, 2022, 2021 and 2020.
4082
      
Tabular List [Table Text Block]
Tabular List of Financial Performance Measures
Dexcom considers the following to be the most important financial performance measures it used to link compensation actually paid to its NEOs, for 2023, to Company performance:
2023 Adjusted Revenue
Non-GAAP Operating Margin
Relative Total Shareholder Return
      
Total Shareholder Return Amount $ 226.92 207.08 245.47 169.02
Peer Group Total Shareholder Return Amount 99.63 105.61 137.80 133.15
Net Income (Loss) $ 541,500,000 $ 341,200,000 $ 216,900,000 $ 549,700,000
Company Selected Measure Amount 3,608,600,000 2,964,900,000 2,422,500,000 1,926,700,000
PEO Name Kevin Sayer      
Measure [Axis]: 1        
Pay vs Performance Disclosure [Table]        
Measure Name 2023 Adjusted Revenue      
Measure [Axis]: 2        
Pay vs Performance Disclosure [Table]        
Measure Name Non-GAAP Operating Margin      
Measure [Axis]: 3        
Pay vs Performance Disclosure [Table]        
Measure Name Relative Total Shareholder Return      
PEO [Member] | Deductions for amounts reported under the “Stock Awards” column in the Summary Compensation Table [Member]        
Pay vs Performance Disclosure [Table]        
Adjustment to Compensation Amount $ (12,486,939)      
PEO [Member] | Year-end Fair Value of Equity Awards Granted During the Year that Remained Unvested as of the End of the Covered Year [Member]        
Pay vs Performance Disclosure [Table]        
Adjustment to Compensation Amount 18,259,324      
PEO [Member] | Vesting Date Fair Value for Awards Granted and Vested in the Same Fiscal Year [Member]        
Pay vs Performance Disclosure [Table]        
Adjustment to Compensation Amount 0      
PEO [Member] | Change in Year-end Fair Value of Equity Awards Granted During Prior Years that Remained Unvested as of the End of the Covered Year [Member]        
Pay vs Performance Disclosure [Table]        
Adjustment to Compensation Amount 1,297,572      
PEO [Member] | Change in Fair Value from Prior Year-end to Vesting Date for Awards Granted in Prior Years that Vested in Covered Fiscal Year [Member]        
Pay vs Performance Disclosure [Table]        
Adjustment to Compensation Amount 216,896      
PEO [Member] | Prior Year-End Fair Value for Awards Granted in Prior Years that are forfeited during the Covered Year [Member]        
Pay vs Performance Disclosure [Table]        
Adjustment to Compensation Amount 0      
PEO [Member] | Net Increases for the Inclusion of Rule 402(v) Equity Values [Member]        
Pay vs Performance Disclosure [Table]        
Adjustment to Compensation Amount 19,773,792      
Non-PEO NEO [Member] | Deductions for amounts reported under the “Stock Awards” column in the Summary Compensation Table [Member]        
Pay vs Performance Disclosure [Table]        
Adjustment to Compensation Amount (3,753,911)      
Non-PEO NEO [Member] | Year-end Fair Value of Equity Awards Granted During the Year that Remained Unvested as of the End of the Covered Year [Member]        
Pay vs Performance Disclosure [Table]        
Adjustment to Compensation Amount 4,485,281      
Non-PEO NEO [Member] | Vesting Date Fair Value for Awards Granted and Vested in the Same Fiscal Year [Member]        
Pay vs Performance Disclosure [Table]        
Adjustment to Compensation Amount 0      
Non-PEO NEO [Member] | Change in Year-end Fair Value of Equity Awards Granted During Prior Years that Remained Unvested as of the End of the Covered Year [Member]        
Pay vs Performance Disclosure [Table]        
Adjustment to Compensation Amount 285,998      
Non-PEO NEO [Member] | Change in Fair Value from Prior Year-end to Vesting Date for Awards Granted in Prior Years that Vested in Covered Fiscal Year [Member]        
Pay vs Performance Disclosure [Table]        
Adjustment to Compensation Amount 38,496      
Non-PEO NEO [Member] | Prior Year-End Fair Value for Awards Granted in Prior Years that are forfeited during the Covered Year [Member]        
Pay vs Performance Disclosure [Table]        
Adjustment to Compensation Amount 0      
Non-PEO NEO [Member] | Net Increases for the Inclusion of Rule 402(v) Equity Values [Member]        
Pay vs Performance Disclosure [Table]        
Adjustment to Compensation Amount $ 4,809,775